Clinical trials: Acromegaly
Acromegaly
Open Label Study of Octreotide Implant in Patients With Acromegaly
To evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) response of a hydrated and non-hydrated 84 mg octreotide implant in patients with acromegaly in the first 6 weeks of treatment.
- Trial name
- NCT00913055
- Testing
- octreotide acetate
- Volunteers
- 34 people
- Sponsor
- Endo USA Inc., a Keenova Therapeutics Company
Acromegaly
A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)
The goal of this clinical trial] is to to Assess the Food Effect on the Relative Bioavailability of Orally Administrated T25 in healthy volunteers. The main questions it aims to answer are： 1.
- Trial name
- NCT07663318
- Testing
- T25-Fast, Mycapssa, T25-Fed
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Triastek (Shanghai) Limited
Acromegaly
Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients
In acromegaly, nearly 40% of patients fail to control GH/IGF-I levels with somatostatin analogues (SA). Dopaminergic agonists (DA) are even less effective, but combination therapy with SA and DA normalizes IGF-I levels in 33-56%…
- Trial name
- NCT01014793
- Testing
- cabergoline
- Where
- Brazil
- Volunteers
- 19 people
- Sponsor
- Federal University of São Paulo
Carcinoid Tumor, Acromegaly
Study of Pasireotide Long Acting Release (LAR) Injection in Patients With Acromegaly and Patients With Carcinoid Disease
This study will assess the pharmacokinetic profile and the safety/tolerability profile of single and monthly doses of pasireotide LAR intramuscular (i.m.) injection in patients with acromegaly and patients with carcinoid disease
- Trial name
- NCT00446082
- Testing
- Pasireotide
- Where
- 17 sites in United States, Belgium and 4 more
- Volunteers
- 85 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
The purpose of this trial is to assess the efficacy and safety of CAM2029 in patients with acromegaly. Patients will be randomized to either CAM2029 or placebo administered subcutaneously once monthly during 6 months.
- Trial name
- ACROINNOVA 1 (NCT04076462)
- Testing
- CAM2029 (octreotide subcutaneous depot)
- Where
- 63 sites in United States, Germany and 8 more
- Volunteers
- 72 people
- Sponsor
- Camurus AB
Acromegaly
One Year Follow-up of Study 2-79-52030-207 (PRIMARYS) in Acromegalic Patients With Macroadenoma
This non-interventional retrospective study aims to describe the therapeutic procedures and modalities received by patients and the correlation to hormone status, during a one year follow up from completion of the 2-79-52030-207…
- Trial name
- NCT01471405
- Where
- 18 sites in Czechia, France and 4 more
- Volunteers
- 54 people
- Sponsor
- Ipsen
Acromegaly
Developing a Simple Recognition System of Acromegaly
We will compare the features of 3D stereophotography of acromegaly patients with that of healthy people. We hope to develop a computerized model to help screening acromegaly patients for early detection and treatment.
- Trial name
- NCT03042026
- Where
- Taiwan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Panhypopituitarism, Gigantism/Acromegaly
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
There is a variety of tumors affecting the pituitary gland in childhood; some of these tumors (eg craniopharyngioma) are included among the most common central nervous system tumors in childhood.
- Conditions
- Panhypopituitarism, Gigantism/Acromegaly, Prolactinoma, Cushing Disease
- Trial name
- NCT00001595
- Testing
- Tissue specimen collection, MRI
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Acromegaly
Octreotide Efficacy and Safety in First-line Acromegalic Patients
Primary Acromegaly is a clinical and metabolic disease caused by growth hormone (GH) hypersecretion from a pituitary adenoma and is an insidious, chronic disease that is associated with bony and soft tissue overgrowth.
- Trial name
- NCT00171886
- Testing
- Octreotide
- Where
- 8 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Novartis Pharmaceuticals
Acromegaly
Quality of Life (QoL) in Subjects With Acromegaly Under Lanreotide Autogel® Treatment.
The purpose of the protocol is to evaluate and describe QoL, in the population of Polish acromegalic patients treated with Lanreotide Autogel® 120 mg during the 24 months (long term observation).
- Trial name
- ACRO QLQ (NCT02396966)
- Where
- 18 sites in Poland
- Volunteers
- 152 people
- Sponsor
- Ipsen
Acromegaly
Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
Octreotide capsule is a novel, orally-administered formulation of the commercially-available injectable drug octreotide. In a recent phase 3 trial (OPTMAL; NCT03252353), oral octreotide capsules demonstrated sustained biochemical…
- Trial name
- MPOWERED (NCT02685709)
- Testing
- Octreotide capsules
- Where
- 53 sites in United States, Austria and 11 more
- Volunteers
- 146 people
- Sponsor
- Chiasma, Inc.
Acromegaly
Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly
Growth hormone (GH) plays a pivotal role in the regulation of body composition including ectopic lipid deposition in insulin sensitive organs like liver and skeletal muscle.
- Trial name
- NCT02115906
- Testing
- 1H/31P Magnetic Resonance Spectroscopy, oral glucose tolerance testing, Thyroid sonography
- Where
- Austria
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Acromegaly
Buccodental Manifestations in Patients With Acromegaly
Context: Acromegaly is the rare condition (3 to 4 new cases per million per year) due to Growth Hormone (GH) overproduction by a somatotrope pituitary adenoma, resulting in Insulin Growth Factor 1 (IGF-1) excess.
- Trial name
- AcroDent (NCT03401008)
- Testing
- Oral manifestations
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Clermont-Ferrand
Acromegaly
Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery
At present there are no recommendations regarding the possibility of discontinuing treatment in cases of recurrent acromegaly with good hormonal control.
- Trial name
- STOP-SST (NCT05149495)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Acromegaly
Estrogen Treatment in Acromegalic Women
Oral estrogens may be an effective adjuvant treatment for control of acromegaly in patients with resistance to somatostatin analogs.
- Trial name
- NCT00315107
- Testing
- Alesse
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- Université de Montréal
Acromegaly
Measurement of Outcome of Surgical Treatment in Patients With Acromegaly
OBJECTIVES: I. Compare growth hormone (GH) levels at baseline and after glucose suppression measured with both a polyclonal radioimmunoassay and a highly sensitive immunoradiometric assay (IRMA) in patients with acromegaly and…
- Trial name
- NCT00005100
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)
Acromegaly
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly
A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (also known as CRN00808; an orally administered nonpeptide somatostatin agonist) in subjects with acromegaly previously treated…
- Trial name
- PATHFNDR-1 (NCT04837040)
- Testing
- Paltusotine
- Where
- 39 sites in United States, Argentina and 12 more
- Volunteers
- 58 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Acromegaly
IGF-I and Free Fatty Acids Isn Glucose Metabolism in Acromegaly
Background Glucose metabolism abnormalities are frequent in acromegaly. Insulin resistance (IR) correlates with the intensity of acromegaly and Insulin-like Growth factor-I (IGF-I) correlates better with IR than growth hormone…
- Trial name
- NCT02084095
- Where
- Romania
- Volunteers
- 16 people
- Sponsor
- Carol Davila University of Medicine and Pharmacy
Acromegaly, Olfactory Disorder
Olfactory Function and Olfactory Bulb Volume in Acromegaly Patients
A prospective, controlled, single blinded study was planned. 20 patients with Acromegaly (Acromegaly Group) and 20 healthy subjects (Control Group) were planned to include in the study.
- Trial name
- NCT04138537
- Testing
- OB volume, CCCRC test
- Where
- Turkey (Türkiye)
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bezmialem Vakif University
Acromegaly
Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly
The objectives of the protocol is to determine the maximum tolerated dose and to investigate the pharmacokinetics of a single dose of lanreotide PRF in subjects with acromegaly.
- Trial name
- NCT02396953
- Testing
- Lanreotide PRF
- Where
- 36 sites in Belgium, Czechia and 10 more
- Volunteers
- 28 people
- Sponsor
- Ipsen